Investor Relations

Latest News

View All News

FibroBiologics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Read Press Release

FibroBiologics Files Patent for Methods of Generating Multipotent Cells from Donor Tissue for Clinical Applications

Read Press Release
employees discussing with whiteboard

Recent Event

Investor Webinar

Company Information

FibroBiologics is a cell therapy, regenerative medicine company developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 150+ US and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy.

View Executive Team
View Board of Directors

Latest Financial Results

Q2 2025

Quarter Ended Jun 30, 2025

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2024

IR Contacts

Company

FibroBiologics, Inc.
455 E. Medical Center Blvd.
Suite 300
Houston, TX 77598
T: 281-671-5150
info@fibrobiologics.com

Investor Relations

Russo Partners
Nic Johnson
T: 212-845-4242
fibrobiologicsIR@russopr.com

Transfer Agent

VStock Transfer LLC
18 Lafayette Place
Woodmere, NY 11598
T: 212-828-8436